-+ 0.00%
-+ 0.00%
-+ 0.00%

Neuphoria Therapeutics Q4 EPS $(0.95) Misses $(0.56) Estimate, Sales $1.174M.

Benzinga·09/18/2026 21:26:11
Listen to the news

Neuphoria Therapeutics (NASDAQ:NEUP) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0.56) by 69.64 percent. This is a 76.13 percent increase over losses of $(3.98) per share from the same period last year. The company reported $1.174 million in sales this quarter.